What Merck actually does

Merck & Co. is a pharmaceutical company headquartered in Rahway, New Jersey. Outside the United States and Canada it operates as Merck Sharp & Dohme (MSD), which is why the name appears in two forms. It is not the same company as the German Merck KGaA, although the two share history.

It sells prescription medicines, vaccines and animal-health products.

How the business makes money

Like other drug makers, Merck depends on patents. While a drug is protected, the company can charge for the value it creates. The most important product by far is Keytruda, a cancer immunotherapy that has become one of the best-selling drugs in the world. Vaccines, such as those for HPV, are another large contributor.

When a patent expires, generic competition arrives and sales fall sharply, so the company must keep launching new treatments.

The dividend story

Merck pays a quarterly dividend and raises it regularly. The yield is moderate and healthy cash flow supports the payout.

The dividend’s long-term safety depends on the pipeline: if new drugs do not replace the ones that lose protection, profit growth slows. See our guide on dividend safety.

What to keep an eye on

  • Patent expiry of its main drug. This is the biggest long-term risk.
  • Pricing rules. Governments and insurers push prices down.
  • Pipeline success. New launches have to deliver.
  • Concentration. Reliance on a few products raises risk.

Quick take

Merck is a strong pharma with a growing dividend. Its challenge is replacing its blockbuster drug before protection ends.